Myotherix
WebSep 1, 2015 · “MyoTherix’s lead research program intends to improve both cardiac and skeletal muscle function, as well as reduce inflammation and facilitate new muscle regeneration,” said John Kincaid, co-Founder of MyoTherix Inc. “We are pleased to work with the team at CureDuchenne and look forward to developing this new approach to the … WebNov 1, 2016 · MyoTherix. November 1, 2016. Approach: Anti-inflammatory, anti-osteoporosis, potential steroid sparing therapies Funding Impact: Industry partnership to sponsor clinical trial for Duchenne. Read More. Capricor Therapeutics. November 1, 2016. Approach: Cardiac stem cell derived therapy
Myotherix
Did you know?
WebSep 1, 2015 · MyoTherix, Inc. is a venture-supported biotechnology company focused on developing novel therapeutics for the treatment of muscle disorders. Its lead product opportunity utilizes an innovative and novel approach to target both cardiac and skeletal muscle weakness. WebMyoTherix is developing therapeutics for the treatment of Duchenne muscular dystrophy. The therapeutics are being developed to improve cardiac and skeletal Research …
WebMyoTherix Inc. - Company Profiles - BCIQ For the biopharma industry investment, business development and competitive intelligence professionals who require information to … WebHe also served as medical advisor to MyoTherix Inc and is a co-founder of PepGen Ltd. Dr. Campion hold bachelors and doctorate degrees in medicine from the University of Bristol and is listed on the General Medical Council (UK) Specialist Register (Rheumatology).
WebMyoTherix's President & CEO, Director, Co-Founder is Michael G. Kelly. Other executives include John Kincaid, Director, Co-Founder; Mark P. de Souza, COO, Director, Co-Founder … WebPhone Number 857-222-4653. MyoTherix is a clinical-stage drug discovery and development company for patients suffering from rare neuromuscular disorders. It is a venture …
WebNEWPORT BEACH, Calif., September 1, 2015 – CureDuchenne Ventures LLC, a company that funds research to find a cure for Duchenne muscular dystrophy, announced today that they have invested $1 million in MyoTherix Inc., a biotechnology company focused on developing novel therapeutics for the treatment of Duchenne and other muscular dystrophies.
WebJun 18, 2024 · He is a Co-Founder and also serves as Executive Chairman at FlightPath Biosciences. He also co-founded and served as Chairman and Chief Operating Officer at MyoTherix. He served as Executive Chairman more Contact Information Primary Investor Type Angel (individual) Primary Office 2600 Tenth Street Suite 435 Berkeley, CA 94710 … cup series qualifying phoenixWebJun 21, 2024 · Anti-Inflammatory Therapy Anti-Fibrosis Therapy Mitochondrial Cardiac Function Muscle Regeneration Muscle Stabilization Cell Therapy * Discontinued means Discontinued at the clinical stage Last Updated 6/21/2024 Share This Page Make an Impact You can advance the care, treatment and cure for Duchenne muscular dystrophy. easy cook slow cooker recipesWebSearch our free database to find email addresses and direct dials for Myotherix employees. easy cook turbo convection ovenWebMyotherix, Inc. Headquarters 29540 Kohoutek Way Union City, California94587 1-857-222-4653 Driving Directions » Myotherix, Inc. Summary ABOUT Overview Myotherix focuses on developing therapies for patients suffering from Duchenne muscular dystrophy and muscle disorders. Myotherix, Inc. was founded in 2013. easy cool christmas cookiesWebJan 2, 2024 · Dr. Michael G. Kelly is a senior pharmaceutical executive with more than thirty years of achievement setting business strategies in building and managing drug discovery … cup series qualifying todayWebInc. Myotherix has a registered in the System for Award Management for doing business with and bidding for contracts by the United States government. Cage Code 72CN4 was listed as their unique company identifier. The company registered with SAM on 2013-12-04 and the registration with the below details. Company Details cups error 1034: bad ppd fileWebMyotherix VentureRadar profile. Find out more about Myotherix, Small Molecule Pharmaceuticals. cup series schedule 2022